Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence

[1]  P. Bach,et al.  Methadone Access for Opioid Use Disorder During the COVID-19 Pandemic Within the United States and Canada , 2021, JAMA network open.

[2]  R. Siliciano,et al.  Non-structured treatment interruptions are associated with higher HIV reservoir size measured by intact proviral DNA assay in people who inject drugs. , 2020, The Journal of infectious diseases.

[3]  N. Volkow,et al.  COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States , 2020, Molecular Psychiatry.

[4]  D. McKay,et al.  COVID-19 stress and substance use: Current issues and future preparations , 2020, Journal of Anxiety Disorders.

[5]  Peter J. Rock,et al.  Signal of increased opioid overdose during COVID-19 from emergency medical services data , 2020, Drug and Alcohol Dependence.

[6]  Ty S. Schepis,et al.  The epidemiology of prescription fentanyl misuse in the United States. , 2019, Addictive behaviors.

[7]  P. Seth,et al.  Changes in Opioid-Involved Overdose Deaths by Opioid Type and Presence of Benzodiazepines, Cocaine, and Methamphetamine — 25 States, July–December 2017 to January–June 2018 , 2019, MMWR. Morbidity and mortality weekly report.

[8]  R. Siliciano,et al.  HIV‐1 latent reservoir size and diversity are stable following brief treatment interruption , 2018, The Journal of clinical investigation.

[9]  D. Perlman,et al.  The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions , 2018, Current HIV/AIDS Reports.

[10]  Xu G. Yu,et al.  Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals , 2018, PLoS pathogens.

[11]  E. Nunes,et al.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial , 2017, The Lancet.

[12]  J. Leung,et al.  Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review , 2017, The Lancet. Global health.

[13]  Daniel I. S. Rosenbloom,et al.  Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics , 2017, The Journal of experimental medicine.

[14]  S. Hughes,et al.  Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir , 2017, PLoS pathogens.

[15]  A. Chakraborty,et al.  Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA , 2016, Proceedings of the National Academy of Sciences.

[16]  M. Jauffret-Roustide,et al.  HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. , 2016, AIDS.

[17]  D. D. Des Jarlais,et al.  HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. , 2016, AIDS.

[18]  C. Timko,et al.  Retention in medication-assisted treatment for opiate dependence: A systematic review , 2016, Journal of addictive diseases.

[19]  K. Silverman,et al.  Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes. , 2015, Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors.

[20]  G. Fitzmaurice,et al.  Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients. , 2014, Drug and alcohol dependence.

[21]  J. Hahn,et al.  Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs , 2014, BMC Public Health.

[22]  J. Ward,et al.  Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010 , 2014, Annals of Internal Medicine.

[23]  F. Altice,et al.  Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners , 2012, PloS one.

[24]  R. D. Bruce,et al.  HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study , 2011, Journal of acquired immune deficiency syndromes.

[25]  F. Altice,et al.  Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment , 2010, Journal of Urban Health.

[26]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[27]  Walter Ling,et al.  Effectiveness of drug dependence treatment in HIV prevention , 2005 .

[28]  Jessica M Malenfant,et al.  Increased Natural Killer Cell Activity in Viremic HIV-1 Infection1 , 2004, The Journal of Immunology.

[29]  Nicole A. Lazar,et al.  Statistical Analysis With Missing Data , 2003, Technometrics.

[30]  M. Farré,et al.  Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. , 2002, Drug and alcohol dependence.

[31]  R. Spitzer,et al.  The PHQ-9 , 2001, Journal of General Internal Medicine.

[32]  R. Siliciano,et al.  Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. , 2000, The Journal of infectious diseases.

[33]  D. Barrett,et al.  Self-reports of alcohol use, drug use and sexual behavior: expanding the Timeline Follow-back technique. , 1998, Journal of studies on alcohol.

[34]  H. Matthes,et al.  Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Power,et al.  Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment , 1998, Psychological Medicine.

[36]  B. Everitt,et al.  Analysis of longitudinal data , 1998, British Journal of Psychiatry.

[37]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[38]  D. Carr,et al.  Naltrexone antagonizes the analgesic and immunosuppressive effects of morphine in mice. , 1994, The Journal of pharmacology and experimental therapeutics.

[39]  O. Aasland,et al.  Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. , 1993, Addiction.

[40]  D. Metzger,et al.  The Fifth Edition of the Addiction Severity Index. , 1992, Journal of substance abuse treatment.

[41]  B. Bayer,et al.  Morphine inhibition of lymphocyte activity is mediated by an opioid dependent mechanism , 1990, Neuropharmacology.

[42]  A. Pert,et al.  The periaqueductal gray matter mediates opiate-induced immunosuppression. , 1989, Science.

[43]  D. Nixon,et al.  HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides , 1988, Nature.

[44]  B. Walker,et al.  HIV-specific cytotoxic T lymphocytes in seropositive individuals , 1987, Nature.

[45]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[46]  P. Westfall,et al.  Multiple comparisons and multiple tests using SAS , 2011 .

[47]  R. Humeniuk,et al.  The Alcohol, Smoking and Substance involvement Screening Test (ASSIST): manual for use in primary care. , 2010 .

[48]  Wuwei Wayne Feng,et al.  A Method/Macro Based on Propensity Score and Mahalanobis Distance to Reduce Bias in Treatment Comparisonin Observational Study , 2006 .

[49]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[50]  B. Efron.  Bootstrap Methods: Another Look at the Jackknife , 1979 .